While precise prevalence data for the MASH-HCC subtype is still emerging, the pathway's role is strongly implicated, as the core metabolic drivers of MASH, such as insulin resistance and hyperinsulinemia, are potent upstream activators of PI3K/Akt signaling 15. This evidence concerns the gene PIK3CA and hepatocellular carcinoma.